Mazdutide

Mazdutide is a synthetic dual agonist of the GLP-1 receptor and the glucagon receptor, derived from the oxyntomodulin scaffold and engineered with fatty-acid acylation for albumin binding to support once-weekly subcutaneous dosing. GLP-1 receptor agonism contributes glucose-dependent insulin release, glucagon suppression at the alpha cell, delayed gastric emptying, and central appetite suppression. Glucagon receptor agonism is hypothesised to contribute additional energy expenditure (hepatic and adipose effects) and lipid-lowering effects independent of GLP-1 signalling. The dual pharmacology is intended to produce greater weight loss than GLP-1 monotherapy at matched glycaemic effect.

Class GLP-1 receptor agonist adverse events (nausea, vomiting, diarrhoea, decreased appetite) predominate in published Phase 2 reports; glucagon receptor agonism raises specific safety questions about hepatic glucose output, lipid effects, and small elevations in fasting glucose at higher doses, although the published Phase 2 data report acceptable glucose effects. Pancreatitis and C-cell concerns from the class apply.

The published Phase 2 evidence base is largely Chinese-population data from the Innovent program; independent Western replication and long-term safety data are not yet available. Dual GLP-1/glucagon agonism is a relatively new pharmacological class — survodutide (Boehringer/Zealand) is the most-developed Western analog; cotadutide (AstraZeneca) was discontinued. Vendor research-grade 'mazdutide' is unlikely to be pharmaceutically equivalent to clinical-grade material.